GI Diet :: Glycemic index values are variable, report researchers

In work investigating the reproducibility of glycemic index values, researchers at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University (USDA HNRCA) have reported that multiple glycemic index value determinations (measure of the rate of glucose absorption into the bloodstream) using a simple test food, white bread, resulted in a relatively high level of inter-individual (among different individuals), and intra-individual (within the same individual) variability.

Diabetes :: Older blacks and Latinos still lag whites in controlling diabetes

Despite decades of advances in diabetes care, African Americans and Latinos are still far less likely than whites to have their blood sugar under control, even with the help of medications, a new nationally representative study finds. That puts them at a much higher risk of blindness, heart attack, kidney failure, foot amputation and other long-term diabetes complications.

Liver :: Quick-burning carbs may cause fatty liver

The obesity epidemic has spawned not just diabetes, but another serious public health problem: a surge in fatty liver disease, which can lead to cirrhosis and liver failure. Now, research suggests that limiting consumption of high-glycemic-index carbohydrates can prevent the condition in mice. A clinical trial is now testing this idea in overweight adolescents, as well as the possibility of reversing fatty liver disease through diet.

Insulin :: Smart insulin nanostructures pass feasibility test, UT study reports

Biomedical engineers at the University of Texas School of Health Information Sciences at Houston have announced pre-clinical test results in the September issue of the International Journal of Nanomedicine demonstrating the feasibility of a smart particle insulin release system that detects spikes in glucose or blood sugar levels and releases insulin to counteract them

Diabetes :: Novartis’ Galvus efficacious in treating patients with type 2 diabetes

Uncontrolled patients with type 2 diabetes treated with metformin, one of the most prescribed oral medicines for this disease, were four times more likely to achieve recommended blood sugar control levels by adding GalvusĀ® (vildagliptin) to their treatment compared to those who added a placebo, according to new clinical data[1].